Related Experiment Video

Updated: Jul 20, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

The use of carvedilol in pediatric heart failure

S C Greenway1, L N Benson

  • 1The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.

Cardiovascular & Hematological Disorders Drug Targets
|May 27, 2006
PubMed

Insights

Carvedilol, a beta-blocker, is effective for adult heart failure. This review examines its use in pediatric heart failure, despite limited supporting data in children.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) presents a significant health burden in both adults and children.
  • While causes of CHF vary between age groups, therapeutic approaches are often similar.
  • Beta-adrenergic receptor blockade is a key treatment for adult CHF.

Purpose of the Study:

  • To review the adult application of carvedilol for congestive heart failure.
  • To assess the existing pediatric literature on carvedilol efficacy in heart failure.
  • To describe institutional experience with carvedilol in pediatric heart failure therapy.

Main Methods:

  • Literature review of adult carvedilol trials for heart failure.
  • Systematic review of pediatric studies on carvedilol in heart failure.
  • Retrospective analysis of institutional data on carvedilol use in pediatric CHF.

Main Results:

  • Carvedilol, a third-generation beta-blocker, demonstrates efficacy and superiority in adult CHF trials.
  • Pediatric use of carvedilol is increasing, but robust efficacy data in infants and children are scarce.
  • Institutional experience provides preliminary insights into carvedilol's role in pediatric heart failure.

Conclusions:

  • Carvedilol shows promise for pediatric congestive heart failure, extrapolated from adult data.
  • Further pediatric-specific research is crucial to establish carvedilol's safety and efficacy in this population.
  • Evidence from adult studies informs the adaptation of carvedilol for pediatric heart failure management.

More Related Videos

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...